Guess which ASX 300 stock is jumping amid huge profit growth

The company is forecasting its profits to more than double in the first half.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Nanosonics Ltd (ASX: NAN) shares are having a strong session on Thursday.

In early trade, the ASX 300 stock is up 6% to $3.97.

A young woman with her mouth open and her hands out showing surprise and delight as uranium share prices skyrocket

Image source: Getty Images

Why is this ASX 300 stock is jumping?

Investors have been buying the infection prevention company's shares this morning following the release of a half-year update.

According to the release, Nanosonics is expecting to report a sizeable increase in revenue and profits for the half after returning to form in FY 2025.

For the six months ended 31 December, the ASX 300 stock expects total revenue to be approximately $93.6 million. This is up 18% from $79.6 million in the prior corresponding period. It is also up 4% from the $90.4 million recorded in the second half of FY 2024.

Commenting on its top line performance during the half, the company's CEO and president, Michael Kavanagh, said:

The expected first half revenue result of $93.6m represents a good start to the year up 18% compared to pcp and 4% compared to H2 FY24. Revenue growth was primarily driven by 20% growth (compared to pcp) in our consumables and service annuity revenue streams. The total number of trophon units sold in the first half was broadly in line with internal forecasts and was similar to the total number sold in the pcp, with overall capital revenue up 11% compared to pcp.

Strong profit growth

The company's gross margin for the half is expected to be approximately 78.5%. This is down from 79.7% in the prior corresponding period but up from 76.3% in the second half of FY 2024.

Nanosonics' operating expenses are expected to be approximately $66.7 million for the half. This is up 10% from the prior corresponding period and 3% on the previous half.

Nevertheless, this couldn't stop the ASX 300 stock from delivering strong profit growth. Management expects a profit before tax of approximately $10.9 million for the six months. This is more than double the $4.9 million recorded in the prior corresponding period and is up from $8.1 million in second half of FY 2024.

CEO Michael Kavanagh revealed that some of this profit growth comes from one-offs. He explains:

As a result of the increased first half revenue, the business expects to deliver profit before tax (PBT) of $10.9 million for the half. The expected PBT result includes a gain of approximately $1.3 million (compared to a $0.4 million loss in H1 FY24) due to the AUD exchange rate moving from 0.66 on 30 June 2024 to 0.62 on 31 December 2024. This movement created an unrealised FX gain on US dollar-denominated assets, partially offset by the group's hedging activities.

Outlook

Kavanagh believes that Nanosonics' first half performance means that it is on track to "achieve revenue, gross margin and operating expenses in FY25 around the top of each of the ranges for those measures specified in Nanosonics' FY25 outlook statement."

This includes total revenue growth of 8% to 12%, a gross margin of 77% to 79%, and operating expense growth of 6% to 10%.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Nanosonics. The Motley Fool Australia has positions in and has recommended Nanosonics. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man in a shirt and tie looks to the horizon holding his hand above his eyes as if to shield the sun so he can see better.
Healthcare Shares

Why is everyone talking about 4DX shares this week?

It's all eyes on the healthcare stock this week.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face.
Healthcare Shares

$10,000 invested in this ASX healthcare share a year ago is now worth $36,500

This stock has experienced a dramatic price increase.

Read more »

A male doctor and a woman in scrubs in the foreground smile.
Healthcare Shares

The ASX healthcare stocks with the biggest upside according to brokers

These two healthcare stocks could be value buys.

Read more »

Cropped shot of a young female scientist working on her computer in the laboratory.
Healthcare Shares

Here's one reason why experts think the CSL share price can rise 65%!

There’s more than one reason why experts are excited by the potential of CSL.

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Forget DroneShield and EOS, this ASX healthcare stock is up 15x in a year!

There is no doubt that 4DMedical is one of the hottest stocks on the ASX right now.

Read more »

Scientists in white coats look disappointed.
Healthcare Shares

$5,000 invested in CSL shares 12 months ago is now worth…

Are the biotech company's shares worth holding onto?

Read more »

Happy healthcare workers in a lab.
Healthcare Shares

Clarity Pharmaceuticals shares are up 12% today. Here's what's driving the move

Today's announcement moves Clarity a step closer towards commercialisation.

Read more »

A medical specialist holds a red heart connected via technology and artificial intelligence.
Healthcare Shares

Which ASX biotech's shares are rocketing higher on big US news?

This company has more than doubled in value over the past three months.

Read more »